These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37511937)

  • 41. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation.
    Hanje AJ; Yao FY
    Curr Opin Organ Transplant; 2008 Jun; 13(3):234-40. PubMed ID: 18685309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination immunotherapy for hepatocellular carcinoma.
    Rimassa L; Finn RS; Sangro B
    J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.
    Biglow L; Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():22. PubMed ID: 34917675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
    Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
    JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
    Nevola R; Delle Femine A; Rosato V; Kondili LA; Alfano M; Mastrocinque D; Imbriani S; Perillo P; Beccia D; Villani A; Ruocco R; Criscuolo L; La Montagna M; Russo A; Marrone A; Sasso FC; Marfella R; Rinaldi L; Esposito N; Barberis G; Claar E
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions.
    Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB
    J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
    Ouyang T; Kan X; Zheng C
    Front Oncol; 2022; 12():898964. PubMed ID: 35785169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.
    Mahmud N; Hoteit MA; Goldberg DS
    Liver Transpl; 2020 Aug; 26(8):977-988. PubMed ID: 32363720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
    Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
    Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liver transplantation for hepatocellular carcinoma: past, present and future.
    Saidi RF; Hejazi Kenari SK
    Middle East J Dig Dis; 2013 Oct; 5(4):181-92. PubMed ID: 24829690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Updated treatment approach to hepatocellular carcinoma.
    Llovet JM
    J Gastroenterol; 2005 Mar; 40(3):225-35. PubMed ID: 15830281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma.
    Song BG; Sinn DH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Kim JM; Joh JW; Choi GS
    Transplant Proc; 2020 Apr; 52(3):881-888. PubMed ID: 32115240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival after Liver Transplant: Influence of Progression of Disease and of Restoration of the "Milan" Criteria in Patients with Hepato-cellular Carcinoma undergoing Down-staging Procedures.
    Giacomoni A; Di Sandro S; Donadon M; Lauterio A; Belli L; Mangoni I; Mihaylov P; Concone G; De Carlis L
    Hepatogastroenterology; 2015 Jun; 62(140):955-61. PubMed ID: 26902036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?
    Yao FY; Fidelman N
    Hepatology; 2016 Mar; 63(3):1014-25. PubMed ID: 26560491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis on intention-to-treat outcomes.
    Di Martino M; Ferraro D; Pisaniello D; Arenga G; Falaschi F; Terrone A; Maniscalco M; Galeota Lanza A; Esposito C; Vennarecci G
    J Hepatobiliary Pancreat Sci; 2023 Apr; 30(4):429-438. PubMed ID: 36207763
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
    Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
    Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current status of therapy for hepatocellular carcinoma.
    Corey KE; Pratt DS
    Therap Adv Gastroenterol; 2009 Jan; 2(1):45-57. PubMed ID: 21180533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
    Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
    Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.